Companies › Vivet Therapeutics SAS
1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Jun 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VTX-801 Replication-deficient recombinant adeno-associated viral vector (rAAV) with liver-tropic c | ATP7B | Phase 1 | Wilson's Disease | Jun 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04537377 | VTX-801 | Phase 1 | Wilson's Disease | Metabolic and endocrine | Jun 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.